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Abstract
Background: Patients undergone kidney transplantation present higher risk of Urothelial Carcinoma (UC) development
and represent a subgroup of special interest. To date, vinflunine is the only drug approved in Europe for the treatment
of advanced UC after failure of platinum-based chemotherapy. However, to our knowledge, no data on the concomitant
administration of vinflunine and immunosuppressive agents are available.
Case presentation: The patient, a 45 years old Caucasian male, presented poorly differentiated UC of the bladder
recurred after initial cystectomy with abdominal lymphadenopathies evidenced by FDG-PET/CT. Previously, at the
age of 22, he had post-glomerulonephritis renal failure and underwent kidney transplantation from deceased
donor. Since then, he has been in treatment with immunosuppressive therapy. At the time of UC recurrence, he
was on treatment with cyclosporine. After progression to platinum-based chemotherapy, he received second-line
therapy with vinflunine resulting in a complete metabolic response after two cycles. However, despite several
dose reductions, the patient experienced severe hematologic toxicity. The pharmacological interaction between
vinflunine and cyclosporine, both metabolized by CYP 3A4, may explain the excellent result and the concomitant
severe toxicity.
Conclusions: Vinflunine is active on UC developed in kidney transplanted patients. However, special attention should
be paid to concomitant administration with immunosuppressive agents that could result in increased toxicity.
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Background
In the USA, bladder cancer ranks 4th and 11th for cancer
incidence in males and females, respectively. Whereas
urothelial carcinoma (UC) accounts for 90 % of all
bladder cancers, superficial UC, defined as non-muscle
invasive cancer, represents 60 % of cases and requires
local therapy with TURB (Trans-Urethral Resection of
Bladder) and subsequent intravesical instillations [1, 2].
UC presents localized muscle invasion or distant metas-
tases in 30 and 10 % of remaining cases, respectively. The
management of muscle invasive disease includes neoadju-
vant or adjuvant chemotherapy associated with cystec-
tomy [2]. Despite surgery, 5-years survival varies between
36 and 48 %. In fact, peri-operative chemotherapy produce
a benefit of approximately 5–7 % and a consistent part of
patients develops recurrence of disease. The treatment of
patients with recurrent or metastatic disease is currently
represented by chemotherapy. As first-line therapy,
Cisplatin and Gemcitabine (CG) demonstrated a similar
efficacy of MVAC (Metotrexate, Vinblastine, Doxorubicin,
Cisplatin) schedule with a more favourable toxicity profile
[3]. Therefore, CG is the preferred option in first-line
setting. However, considering that UC mainly develops in
elderly patient (with a median age at diagnosis of approxi-
mately 70 years), the event of treating a patient un-fit for
cisplatin is not unusual [4]. Un-fit patients are defined by
the presence of at least one of the following: Eastern Co-
operative Oncology Group Performance Status (ECOG PS)
= 2, clearance of creatinine < 60 mL/min, grade ≥ 2 hearing
loss or peripheral neuropathy [according to National
Cancer Institute Common Terminology Criteria for Ad-
verse Events (NCI-CTCAE)], heart failure (New York Heart
Association functional classification class III). In these
cases, carboplatin instead of cisplatin may be an option [5].
So far, vinflunine (VFL) is the only drug approved after
failure of platinum-based treatment in Europe. It has
been registered on the basis of a phase III trial that com-
pared VFL versus best supportive care in second line
setting, demonstrating a benefit of 2.6 months in median
overall survival (OS) [6]. Principal VFL-related side ef-
fects include: constipation, anemia, neutropenia, vomit-
ing and stomatitis. However, VFL has been proved to be
acceptable also for elderly patients if dose reduction and
granulocyte-colony stimulating factors (G-CSF) prophy-
laxis are observed [7]. With this evidence, the activity of
a VFL based doublet as first-line therapy has been
successfully explored in a phase II trial conducted in pa-
tients un-fit for cisplatin and a phase III trial comparing
VFL-gemcitabine versus carboplatin-gemcitabine in the
same setting is ongoing [8]. Even if preliminary data of
check-point inhibition are encouraging also in UC pa-
tients, results from ongoing randomized trials will not be
available before a couple of years [9, 10]. In conclusion,
chemotherapy still play a crucial role in UC management
and VFL is expected to be one of the protagonists in the
next years scenario.
Smoking habit is the most important risk factor associ-
ated with the development of UC in west countries. An-
other well known risk factor is the exposition to aromatic
amines and aniline derivatives [11]. Recently, a higher inci-
dence of UC has been documented in a large series of
patients who received renal transplantation [12]. Authors
evidenced that patients diagnosed with bladder UC after
renal transplantation were younger and presented more
aggressive and advanced disease. The immune suppression
required after transplantation is considered to support UC
carcinogenesis process. Therefore, post-transplantation pa-
tients represent a particular subgroup of UC patients re-
quiring special attention due to their comorbidity and
concomitant immunosuppressive medications.
Here, we present a case report of a young kidney-
transplanted patient who presented complete metabolic
response after two cycles of second-line VFL chemother-
apy. To our knowledge, this is the first report attesting
the use of VFL in a patient under immunosuppressive
therapy for kidney transplantation.
Case presentation
At the time of diagnosis, the patient, a Caucasian male,
was 45-years-old. His past medical history included
hypertension, hyperuricemia, previous asymptomatic
myocardial infarction and anti-HCV positivity. In 1988
post-glomerulonephritis renal failure occurred and he
was treated with dialysis for 13 months. Subsequently, in
1989 the patient underwent kidney transplantation from
deceased donor and since then immunosuppressive ther-
apy was introduced. The oncological history started in
February 2013, when a routinary abdominal ultra sound
(US) exam, performed in another institution, evidenced
a bladder wall thickening. Subsequent cystoscopy was
performed showing suspect eteroplastic lesion. TURB
revealed poorly differentiated transitional cell bladder
carcinoma. In May 2013 TURB was repeated showing
poorly differentiated carcinoma with neuroendocrine
features. In June 2013, the patient had partial cystectomy
plus lymphoadenectomy. The histology confirmed high
grade UC with lymphatic invasion (stage pT2N0); immu-
nohistochemistry resulted strongly positive for Ki-67
(100 %), negative for cromogranin-A, neuron-specific
enolase, somatostatin receptor 2 antibody and synapto-
physin. During follow-up, the patient underwent regular
cystoscopies and in January 2014 the biopsy of a sus-
pected mucosal area showed residual poorly differenti-
ated carcinoma with focal CD56 stain. Therefore, in
March 2014, radical cystectomy was completed with
final histological report of poorly differentiated carcin-
oma with neuroendocrine features (pT1N0). During
follow-up, a 18-F-fluorodeoxyglucose-positron emission
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tomography/computed tomography (FDG-PET/CT)
performed in July 2014 showed the appearance of patho-
logical uptake localized to confluent right iliac and retro-
aortic lymph nodes.
The patient came in our institution for the first time in
August 2014 to discuss the initiation of first line chemo-
therapy. At that time, he was in therapy with cyclosporine
125 mg/die as immunosuppressive treatment. Therefore we
considered to start chemotherapy with dose reduction as
precaution. He started gemcitabine 1000 mg/m2 (day 1,8)
on 27th August 2014 and carboplatin AUC 3 (day 1) was
added from the second cycle. During the treatment, the
patient developed subsequent adverse events (AEs accord-
ing to NCI-CTCAE version 4): anemia grade (G) 2,
thrombocytopenia G1, neutropenia G3, ALT increased G2
and nausea G1. These AEs entailed dose delay and further
dose reduction. A FDG-PET/CT was planned after 3 cycles
and showed partial response. He completed 6 cycles of
treatment but subsequent PET/CT, performed on February
2015, demonstrated progressive disease due to numeric
increase of captating bilateral common iliac and paraortic
adenopathies (Figs. 1a and 2a). On 27th February 2015 the
patient started second line treatment with VFL 280 mg/m2.
After the first cycle the patient presented oral mucositis
G1, loss of appetite and nausea G1 and prolonged G4
neutropenia that required precautionary hospital admission
and administration of G-CSF and antibiotic prophylaxis.
Considering the severe haematological toxicity, the second
cycle was prescribed with further dose reduction (220 mg/
m2) and G-CSF prophylaxis. Despite this, after the second
cycle, neutropenia G4 and thrombocytopenia G4 occurred.
In April 2015, FDG-PET/CT after two cycles documented
complete metabolic response with disappearance of adeno-
pathic pathological uptake (Figs. 1b and 2b). Chemotherapy
proceeded with further dose reduction to 200 mg/m2 plus
G-CSF prophylaxis and treatment was well tolerated with
the exception of G2 temporary transaminases increase.
In July 2015, before the 6th cycle, patient presented
gastroenteritis and diarrhea (seven stools/die for three
consecutive days) with consequent acute renal failure (cre-
atinine 5.5 mg/dL, clearance 23 ml/min). He was admitted
to hospital and adequate hydration and supportive care was
administered. After resolution of renal failure, which was
considered not related to VFL, patient received the 6th and
last cycle. After treatment completion, FDG-PET/CT was
repeated showing pathological captation of inter aortic-
caval and right common iliac nodes. A multidisciplinary
team decided for stereotactic radiotherapy on pathological
nodes that the patient received in November 2015. A new
FDG-PET/CT was planned for the end of January 2016, 2
months after the completion of radiotherapy, and revealed
a partial metabolic response to radiotherapy. Then the
patient was followed with close clinical and radiological
controls.
Conclusions
Here we report the case of a young kidney transplanted
patient affected by advanced UC of the bladder and
treated with second-line chemotherapy with VFL. To
our knowledge, nothing has been previously reported
regarding VFL therapy in patients with organ transplant-
ation and immunosuppressive therapy. However, in
patients undergone kidney transplantation evidence for
an increased risk of aggressive UC development has
recently been provided. Thus, the event of treating
transplanted patient could be not so rare and sharing
our experience could be relevant for other clinicians.
Accordingly to what reported by Yan and colleagues, the
clinical behaviour of UC in our patient was highly aggres-
sive [12]. This is consistent with the histo-pathological
characteristics of the tumour such as neuroendocrine
features, CD56 stain and extremely high proliferation index
(Ki67 100 %). These factors were implicated in the two
relapses occurred in our patient history that required rad-
ical cystectomy and the initiation of systemic chemotherapy
later, when disease relapsed in advanced stage.
Fig. 1 Para-aortic lymphodenopaties before therapy with vinflunine (VFL) (a) and after treatment (b)
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Our patient did not present any of the known princi-
pal negative prognostic factors for second line chemo-
therapy [13]. In fact, when chemotherapy was initiated
for systemic recurrence Hb was higher than 10 g/dL, PS
was 1, visceral and bone metastases were absent. As
previously described, the patient experienced a signifi-
cant response to VFL therapy considering the FDG-
PET/CT after two cycles showed complete metabolic re-
sponse. This was achieved despite the aggressiveness of
histo-pathological features mentioned above and we
argue that the absence of negative predictive factors
could have play a role in reaching this result.
Nevertheless, treatment-related toxicity was the coun-
terpart of the brilliant result in disease remission. In fact,
during treatment patient presented serious side effects
related to VFL that determined several dose reductions
and required hospital admission and prophylaxis with
antibiotic for severe neutropenia. Moreover, the patient
also had an admission due to acute renal failure conse-
quent to severe diarrhea complicating an episode of
gastroenteritis. Although this event is not likely to be re-
lated to VFL therapy, it emphasizes the frailty of patients
with kidney transplantation. Before starting therapy, we
investigate the potential pharmacologic interaction between
immunosuppressive therapy and VFL. During treatment
with VFL, the patient was on therapy with cyclosporine as
immunosuppressive agent. Both VFL and cyclosporine are
prevalently metabolized by cytochrome CYP3A4 [14]
(http://www.ema.europa.eu/docs/en_GB/document_library/
EPAR_-_Product_Information/human/000983/WC5000396
04.pdf). Therefore, we hypothesize that during the con-
comitant administration, VFL and cyclosporine competed
for the same cytochrome with a consequent reduction in
their metabolism. For this reason, and considering the pa-
tient as frail, we decided to start therapy with 280 instead
of 320 mg/m2. However, despite the initial dose reduction,
our patient presented several serious AEs, suggesting us
that drug interaction was more strong than expected. Our
observation is limited by the fact that plasmatic levels of
cyclosporine and of VFL have not been determined during
treatment and therefore definitive conclusions can not be
drawn. However, our hypothesis deserves to be evaluated in
future patients.
In conclusion, patients with kidney transplantation
present a higher risk of developing UC of the bladder. In
this event, UC is highly aggressive and almost always
spread with distant metastasis thus requiring a systemic
chemotherapy treatment. Despite the young age, trans-
planted patients should be considered frail because of
their past medical history and concomitant medications.
VFL is the only chemotherapy registered after progres-
sion to platinum-based chemotherapy in UC. In this
particular subset of patients, VFL is active and can be
used in clinical practice. However, more attention should
be paid to VFL dosage due to the high risk of toxicity
probably related to pharmacological interaction between
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